Thane Wettig
Chief Executive Officer at FIBROGEN, INC.
Net worth: 1 M $ as of 2024-03-30
Profile
Thane Wettig is currently the Chief Executive Officer & Director at FibroGen, Inc. He previously worked as the Chief Commercial Officer at Intarcia Therapeutics, Inc. and as the Vice President-Diabetes Brands Global Marketing at Lilly Diabetes from 2004 to 2009.
Mr. Wettig completed his undergraduate degree and MBA at Washington University in St. Louis.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
FIBROGEN, INC.
0.48% | 2024-03-21 | 470,396 ( 0.48% ) | 1 M $ | 2024-03-30 |
Thane Wettig active positions
| Companies | Position | Start |
|---|---|---|
| FIBROGEN, INC. | Chief Executive Officer | 2023-07-22 |
Former positions of Thane Wettig
| Companies | Position | End |
|---|---|---|
| Lilly Diabetes | Corporate Officer/Principal | 2008-12-31 |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
Training of Thane Wettig
| Washington University in St. Louis | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| FIBROGEN, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
| Lilly Diabetes |
- Stock Market
- Insiders
- Thane Wettig
